Metadata
Dataset ID:
8
Study Design
| Study Design Background | Synthesis and labelling with F-18 of (2S,4R)-4-fluoroglutamine (4-FGln). In vitro evaluation using two cancers cell line and in vivo imaging in a multiple myeloma mouse model, in comparison to 18F-FDG. Evaluation of Bortezomib treatment efficacy. |
|---|---|
| Study Description | Chemical synthesis and characterization of 4-FGln. In vitro and in vivo evaluation by PET-CT of the new radiotracer [18F]4-FGln in the multiple myeloma detection and treatment. Comparison to [18F]FDG |
| Study Type | preclinical |
| Study Subtype | in vivo and ex-vivo |
Publication
| Paper Linked | yes |
|---|---|
| Paper Title | [18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma |
| Paper Authors | Valtorta S, Toscani D, Chiu M,…Moresco RM, … and Giuliani N |
| Affiliation | University of Milano - Bicocca, University of Parma, IRCCS San Raffale of Milan, IBFM-CNR, Italy |
| Paper Journal | Frontiers in Oncology |
| Paper Year | 2021 |
| Paper Doi | https://doi.org/10.3389/fonc.2021.760732 |
| Open Access | yes |
| Updated Year | 2022 |
Study Component
| Multi Modality Images | not |
|---|---|
| Imaging Modality | PET |
| Radiation | yes |
| Imaging Coverage | PET: whole body |
| Imaging Target | Glutamine and glucose metabolism |
Dataset Information
| Institution | IBFM-CNR |
|---|---|
| Pi | Moresco Rosa Maria |
| Co Pi | Valtorta Silvia |
| Country Of Institution | Italy |
| Imaging Facility | Laboratory of molecular imaging for small animal |
| Euro Bio Imaging Node | MMMI |
| Country Of Imaging Facility | Italy |
In Vivo Experimental Parameters
| Number Of Groups | 2 tumor models: asyngeneic model (murine Vk12598 cells) and a xenograft model (JJN3 cells). JJN3 used also for treatment response. |
|---|---|
| Types Of Groups | 1. syngeneic model (murine Vk12598 cells) for tracer biodistribution 2. xenograft model (JJN3 cells) for kinetic and biodistribution 3. JJN3 xenograft model control group (treated with vehicle) 4. JJN3 xenograft model control group (treated with Bortezomib) |
| Overall Sample Size | 27 |
| Disease Model | multiple myeloma |
| Organ Or Tissue | total body |
| Sample Size For Each Group | group 1: 5; group 2: 7; group 3: 8; group 4: 7. |
| Power Calculation | G*power |
| Randomization | mice were randomly assigned to control or treated group |
| Blinding | no |
| Outcome Measures | Relative tumor growth, weight loss, general well being of the mice |
| Statistical Methods | Unpaired t test and Wilcoxon matched-pairs signed rank-test and Unpaired Mann-Whitney test. |
| Species | Mice |
| Strain | C57BL/6J, NOD.SCID |
| Immune Status | Immunecompetent and immunodeficient |
| Sex | Female |
| Age | Older than 6 weeks |
| Age At Start Experiment | Older than 6 weeks |
| Age At Scanning Experiment S | Older than 6 weeks |
| Weight | About 25 g |
| Weight At Start Experiment | About 25 g |
| Weight At End Experiment | About 25 g |
| Source Of Animals | Charles river Laboratories |
| Registry Number Of Animal Authorization | 34/2018-PR |
Experimental Procedures
| Pharmacological Drug | Bortezomib |
|---|---|
| Company | n.a. |
| Formulation | Solution |
| Drug Dose | 1 |
| Volume | 0,03 |
| Concentration | 1 mg/ml |
| Site Route Of Administration | intravenous |
| Frequency Of Administration | two times (d0 and d4) |
| Vehicle Or Carrier Solution Formulation | Saline |
| Drug Batch Sample Number | n.a. |
| Blood Sampling | yes |
| Blood Sampling Method | retroorbital bleeding |
| Blood Sample Volume | 50 ul |
| Blood Timing | one a week for 3 weeks in the syngeneic model |
| Surgical Procedures Including Sham Surgery | no |
| Pathogen Infection Intervention And Control | no |
| Analgesic Plan To Relieve Pain Suffering And Distress | no |
| Anesthesia Type | Gas |
| Duration | 30 |
| Anesthesia Drugs | Isofluran |
| Anesthesia Dose | 2% in 1L per minute/air mix |
| Monitoring Regime | software remote control of the animal's vital functions (temperature, heartbeat and breathing) |
| Euthanasia | yes |
| Method | CO2 plus cervical dislocation |
| Histology | no |
| Frequency Of Imaging | 2-3 time point for both radioligands |
| Timing Of Imaging | cell line Vk12598: three time points (1 per week after cells injection); cell line JJN3: two time points (one and two weeks and before and after treatment) |
| Overall Scan Length | 90 min for PET-CT kinetic of [18F]4-FGln; 30 minutes for PET-CT biodistribution and therapy response |
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule | Yes |
| Contrast Agent Commercial Drug | [18F]4-FGln; [18F]FDG |
| Contrast Agent Chemical Drug | 18F-(2S,4R)-4-fluoroglutamine; 18F-fluorodeoxyglucose |
| Contrast Agent Dose | 4.32 ± 0.23MBq; 4.46 ± 0.41 MBq |
| Injection Volume | 0,03 |
| Injection Time | scanning 15 and 60 minutes from tracer injection |
| Vehicle | saline |
| Route Of Administration | intravenous |
| Cell Line | Vk12598 cells (cell line 1); JJN3 HMCL cells (cell line 2) |
| Provenance | Leibniz Institute Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig,Germany) and from Vk*MYC transgenic mouse |
| Cell Injection Route | Vk12598 cells: i.v.; JJN3 HMCL cells: subcutaneous |
| Number Of Cells | 0.5 × 10^6 for cell line 1; 5 × 10^6 for cell line 2 |
Image Acquisition
| Instrument Vendor | ISE s.r.l. |
|---|---|
| Instrument Type | YAP-(S)-PET II |
| Instrument Specifics | PET: FOV of 40x40 mm |
| Image Acquisition Parameters | PET: 511 KeV, 30% energy resolution. |
| Correction | PET: isotope decay and random coincidences correction |
| Raw Data | Yes |
| Qa Qc | Yes. Annual QC |
Image Correlation
| Image Type | Reconstructed and quantified images |
|---|---|
| Image Scale | KBq/cc for PET |
| Format Compression | raw, DICOM |
| Dimensions | 3D |
| Overall Number Of Images | 1 dataset per animal per time point |
| Field Of View | Max FOV for PET |
| Dimension Extents | 128 x 128 x 27 |
| Size Description | 40 x 40 x 40 mm |
| Pixel Voxel Size Description | 0,3125 x 0,3125 x 1,5 mm |
| Image Reconstruction Algorithm | PET: EM (30 iterations) |
| Quality Control | no |
| Image Registration Algorithm | no |
| Ai Enhanced Algorithm | no |
| Corrections | PET: acquisition decay, randoms |
| Spatial And Temporal Alignment | no |
| Coregistered Images | no |
Analyzed Data
| Analysis Result Type | regional increase of radiotracer's uptake |
|---|---|
| Data Used For Analysis | VOIs analysis, SUV |
| Analysis Method And Details | PMOD |
| Status | complete |
Ontology Terms
| Ncit Imaging | NCIT:C17007 |
|---|---|
| Doid | DOID:9538 |
| Ncit Species | NCIT:C14238 |
| Ncit Strain | NCIT:C15167 |
| Chebi Pharmaco | CHEBI:52717 |
| Chebi Anesthesia | CHEBI:6015 |
| Chebi Contrast Agent Commercial Name | CHEBI:49134 |
| Chebi Contrast Agent Chemical Name | CHEBI:49134 |
| Clo | CLO_0037173 |